Apollomics (NASDAQ:APLM) Stock Rating Lowered by Wall Street Zen

Apollomics (NASDAQ:APLM) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Apollomics in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Apollomics Price Performance

APLM opened at $20.90 on Friday. Apollomics has a 12 month low of $3.66 and a 12 month high of $42.12. The stock has a fifty day moving average price of $17.39 and a 200-day moving average price of $12.45.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.